BioSpace News Archive

Bracco Diagnostics Inc. announced that the U.S. Food and Drug Administration has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent, which shows the highest relaxivity compared to all the other GBCAs available today in the United States.i,ii Gadopiclenol Injection will be commercialized by Bracco as VUEWAY injection and VUEWAY Pharmacy Bulk Package.

SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy, the most advanced non-surgical technology for the treatment of common skin cancers, announced the availability of the technology in South Dakota.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced it will present additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 28 – October 1, 2022 at the New York Hilton Midtown in New York, New York.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase) today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Grand Challenges in Parkinson’s Disease Conference.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer, and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer.

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published detailed results from the Phase 3 VALOR study and the combined analysis of VALOR and its open label extension (OLE) study evaluating tofersen for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, and the first to bring a macrocyclic GBCA to the global market, is proud to announce the U.S. Food and Drug Administration (FDA) has approved Elucirem™ (gadopiclenol) injection.

ALX Oncology Holdings Inc. announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28 in New York.

Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.